Teal Corner Page Header
Power to Scale

Preclinical Testing Made Easy

Prior to clinical studies, safety and efficacy must be tested in multiple species. Use the NanoAssemblr Blaze to achieve:



Speedy And efficient


Efficient formulation for large preclinical studies.



Easy Scale-up


Easy scale-up of formulations developed on the NanoAssemblr® Ignite.


High Capacity


Greater formulation capacity with the simplicity and efficiency of the NanoAssemblr® Ignite.


Validation of Inline Dilution


Validation of Inline Dilution up to 5L, up to 50 L with Blaze+.



High Range of Formulation


Formulation of 10 mL to 1L batches, up to 10 L with the Blaze+.



Scalable Upstream and Downstream


Scale-up development of upstream and downstream processes.

Accelerate Late Preclinical Development
Larger Volumes with Blaze+ Upgrade

Up to 10 Liters per formulation


Connect bioprocess bags for closed system


Reduce cost by performing process development in house


Accelerate timelines by performing large scale formulations

Versatile Scalability
Using the same microfluidic geometry, formulations are scalable across the NanoAssemblr® platform. This greatly reduces process and formulation redevelopment when changing scales, compared to conventional batch-based methodologies. LNPs containing nucleic acids maintain identical size and PDI when scaled across the platform.
NanoAssemblr Cartridge Comparison


Particle Size, Polydispersity and RNA Encapsulation Efficiency were Consistent as Production of Epo-encoded mRNA-LNP was Scaled using the NanoAssemblr® Platform


Nanoparticle Size at Every Scale
EE At Every Scale

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch
Case Study
Advanced Pre-clinical Studies Require Scalable Production Enabled by NanoAssemblr Technology
In a 2017 study, researchers from MD Anderson and Arcturus Therapeutics describe an immuno-oncology treatment for intracerebral glioma based on microRNA delivered by lipid nanoparticles. Their study involved escalating dose and repeat dose studies in a large model.
Based on stated doses, it is estimated that over 100 mL of formulation would be required per replicate to carry out this experiment. Their study involved 6 replicates. The NanoAssemblr® Blaze with a capacity of up to 1000 mL is ideal for reproducible formulation for advanced preclinical studies.
NanoAssemblr Blaze Case Study
Advanced Technology for Advanced Genetic Medicines
Non-turbulent microfluidic mixing provides unparalleled control over nanoparticle assembly that is scalable from discovery to the clinic.


An aqueous phase and a miscible solvent containing dissolved nanoparticle precursors are injected into each inlet of the NanoAssemblr cartridge


Under laminar flow, the two phases do not immediately mix


Microscopic features engineered into the channel reproducibly control the mixing of the two streams


Rapid, controlled, homogenous mixing produces homogeneous nanoparticles
NanoAssemblr® Technology


Blaze Formulation Demonstration Video


Blaze Informational Presentation


Blaze Demonstration

Blaze Cartridges
NanoAssemblr Blaze™ NxGen cartridges are the same as the cartridges on the GMP System, so parameters can be directly transferred between instruments to accommodate different scales of production. Cartridges are single-use and available with and without in-line dilution. Blaze cartridges are sold individually.
NanoAssemblr Blaze Cartridge
Blaze Brochure
Blaze BrochureThe NanoAssemblr Blaze allows rapid scaling of nanoparticle formulations for late pre-clinical development. The system can manufacture between 10 mL and 10 L of formulation which allows researchers to use the Blaze for preclinical toxicology testing, and for early Chemistry, Manufacturing and Controls (CMC) studies.

Download Brochure

Resource Center


August 31, 2022

Solving Challenges in Manufacturing of mRNA Drug Products: Rapid Development and Scale-Up of a Model mRNA Ther...

Read More 阅读更多 PDF


November 09, 2021

Accelerated Development of Self-amplifying mRNA (saRNA) Vaccines using Microfluidics

Read More 阅读更多 PDF

Publication - Abstract

November 29, 2018

International Journal of Pharmaceutics

Rapid and Scale-independent Microfluidic Manufacture of Liposomes Entrapping Protein Incorporating In-line Pur...

N. Forbes, MT. Hussain, ML. Briuglia, DY. Edwards, JH. terHorst, N. Szita, Y. Perrie

Read More 阅读更多

Application Note

July 01, 2018

Seamless scale up of liposomal verteporfin formulations using the NanoAssemblr® Platform

Read More 阅读更多 PDF


June 11, 2018

Rapid development and seamless scale-up of genetic nanomedicines

Read More 阅读更多 PDF


April 01, 2018

A Scalable Microfluidics Platform for the Development of Nanoparticles

Read More 阅读更多 PDF
Resource Center 资源中心